OncoReHub AI Rehabilitation Funded by Innova Invest
DyCare is driving the future of digital health with OncoReHub, an AI-powered oncology rehabilitation platform designed to improve remote monitoring, personalised rehabilitation, and treatment adherence for cancer patients.
By combining artificial intelligence, computer vision, and virtual assistants, the project aims to transform oncology rehabilitation through a more accessible, data-driven, and patient-centred approach to care.
In this interview, the DyCare team shares the vision behind OncoReHub, the challenges of integrating AI into clinical practice, and how the platform could redefine the future of oncology telerehabilitation and healthcare sustainability.
Supported by the Innova Invest programme, the project secured funding of over € 282K to accelerate the development and international validation of the solution.
1. What do you consider to be the biggest innovation that OncoReHub brings to oncology rehabilitation?
The greatest innovation behind OncoReHub lies in the integration of a unique technological ecosystem that combines artificial intelligence, computer vision, and virtual assistants to deliver truly personalised and adaptive rehabilitation. Unlike traditional solutions, OncoReHub does not simply digitise exercises: it performs an automated initial diagnosis, evaluates mobility in real time, considers the specific limitations caused by surgeries and aggressive cancer treatments, and dynamically adjusts therapies according to the patient’s progress.
In essence, we bring the specialist consultation into the patient’s home while maintaining clinical rigour and adding a level of continuous monitoring that is impossible to achieve through conventional methods.
2. In your experience, what are the main challenges in integrating a telerehabilitation platform such as OncoReHub into the daily clinical practice of hospitals and oncology centres?
The challenges are both technological and cultural. From a clinical perspective, it is essential that the platform integrates seamlessly with existing hospital information systems while meeting the highest standards of data security and protection.
At the same time, there is a significant challenge in adoption among healthcare professionals, who need to trust the recommendations generated by AI and recognise their added value in day-to-day practice.
We also face the challenge of ensuring accessibility for patients of all ages and digital literacy levels, especially within an oncology population where fatigue and emotional conditions can create additional barriers. This is why we designed an intuitive interface and a voice assistant that greatly simplify interaction.
3. OncoReHub combines artificial intelligence, computer vision, and predictive analytics. Could you tell us more about the process of integrating these technologies into a single functional and safe solution for patients?
It was an iterative and multidisciplinary process that required close collaboration between software engineers, deep learning experts, physiotherapists, oncologists, and patients themselves.
We started with biomechanical analysis through computer vision, which enables mobility assessment without the need for wearables or invasive devices. On top of that layer, we developed deep learning algorithms capable of generating personalised exercise programmes, and later incorporated an intelligent voice assistant able to conduct validated clinical questionnaires for oncology patients.
The key was designing the solution from the outset under “privacy by design” principles and continuous clinical validation, ensuring that every algorithmic decision was explainable, traceable, and supervised by healthcare professionals.
4. The project involves collaboration with hospitals in Spain, Colombia, and Andorra. How were these partners selected, and what role do they play in clinical validation?
The selection was based on three key criteria: clinical excellence in oncology, research capabilities, and diversity of patient profiles.
Institutions such as Hospital Vall d’Hebron, the Valencian Institute of Oncology (IVO), and the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Centre in Colombia provide not only scientific rigour, but also the opportunity to validate OncoReHub across different healthcare settings, workflows, and socioeconomic patient profiles.
Their role is essential: they lead multicentre clinical trials, provide continuous clinical feedback, and help us refine both the algorithms and the user experience. This geographical diversity also allows us to ensure the solution is scalable and culturally adaptable.
5. Beyond breast and lung cancer, do you see OncoReHub expanding into other types of cancer or even other therapeutic areas?
Absolutely. Breast and lung cancer were our starting points due to their high prevalence and the complexity of their physical side effects, but the technological architecture behind OncoReHub was designed from the beginning to be modular and scalable.
We are already exploring applications in colorectal cancer, head and neck cancer, and haematological conditions.
Beyond oncology, we see enormous potential in other areas where functional rehabilitation plays a key role, such as post-stroke neurorehabilitation, recovery after orthopaedic surgeries, and the management of chronic diseases such as COPD.
The philosophy remains the same: personalisation, remote supervision, and continuous improvement based on real clinical data.
6. OncoReHub is expected to significantly reduce healthcare costs and CO₂ emissions. What impact do you believe this solution will have on the sustainability of healthcare systems?
The impact could be transformative on two levels.
On the one hand, there is economic sustainability: we estimate direct annual savings of €12.5 million in Spain alone, resulting from reducing in-person sessions by up to 53% and increasing treatment adherence to 80%. This frees up hospital resources that can be redirected toward more complex cases.
On the other hand, there is environmental sustainability: by avoiding unnecessary travel for thousands of patients and healthcare professionals, we significantly reduce the CO₂ emissions associated with healthcare systems.
At a time when European healthcare systems are facing challenges linked to ageing populations and increasing budget pressures, solutions such as OncoReHub are not a luxury, but a strategic necessity.
7. What has your experience been like working with Evolution Europe, and how has the support received contributed to the project’s growth and international positioning?
Our experience with Evolution Europe, and particularly with Innova Invest, has been instrumental in bringing OncoReHub from concept to clinical reality. Beyond financial support, we received strategic guidance that allowed us to structure the project with an international vision from its earliest stages.
Innova Invest’s ability to connect technology, healthcare, and markets has been key in opening doors for us in Spain, Colombia, and Andorra, and in positioning us as a benchmark in oncology telerehabilitation.
We especially value the confidence placed in such an ambitious scientific and technological innovation, as well as the long-term vision they share with us: turning OncoReHub into a global solution capable of improving the lives of thousands of cancer patients worldwide.
